

ACQUISITION OR INVESTMENT OPPORTUNITY

Revolutionary automated pharmacy dispensing platform

Company Overview

- PCAS Patient Care Automation Services Inc. (“PharmaTrust” or the “Company”), is a healthcare technology company that has developed and is commercializing a unique, automated pharmacy dispensing platform.
- Established in 2006 and headquartered in Oakville, Ontario, the Company’s principal technology and product is The PharmaTrust MedCentre™, a pharmacist-controlled, customer interactive, prescription dispensing system akin from a patients perspective to a “pharmacy-in-a-box” or prescription ATM.
- The Company believes that The PharmaTrust MedCentre™ is currently the only commercial, scalable, platform-enabled and fully-automated remote dispensing solution for pharmaceuticals available today.
- PharmaTrust has invested over \$67 million to date in developing The PharmaTrust MedCentre™ and ensuring enterprise ready capability. The Company has successfully deployed 16 trial MedCentres™ in Canadian hospital and clinical settings and completed initial testing with a large US retail pharmacy chain.
- As a result of the large investment in building the technology and security platform, combined with the inability to raise suitable additional capital to complete the commercialization of The PharmaTrust MedCentre™ in line with PharmaTrust’s original plan, the Company obtained a stay of proceedings under the Companies’ Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended (the “CCAA”) in order to enable it to restructure its business. PricewaterhouseCoopers Inc. was appointed as monitor (“the Monitor”) under the CCAA.
- Interested parties are being provided with an opportunity to participate in a sale and investor solicitation process.



Investment / Acquisition Highlights

- ✓ **Field-tested and customer-validated technology with first-mover advantage**
 - Technological leadership positions the Company to be the first-mover in attracting strategic partners and securing significant market share of key high-traffic sites across target markets.
 - First-mover advantage secured by 29 apparatus and business method patents pending, covering PharmaTrust’s key global target markets and relating to The PharmaTrust MedCentre™, supporting infrastructure and complimentary products.
 - Product specifications or plans in place for a number of complimentary technologies including a home based compliance technology (MedHome™).
 - In April 2012, the Company commissioned a detailed review by industry-leading technology experts which validated PharmaTrust’s core technology and its potential.
- ✓ **Opportunity to capitalize on current healthcare and demographic trends**
 - Ageing population and increasingly complex health conditions are driving demand for drug therapies and healthcare services.
 - Patients are playing a more active role in personal healthcare decisions as a means of controlling costs and increasing convenience.
 - Governments and private payors are seeking innovative ways to contain escalating healthcare costs.
 - The technology enables real-time data collection and connection with payors and providers to help manage and coordinate accountable healthcare programs.

ACQUISITION OR INVESTMENT OPPORTUNITY

Revolutionary automated pharmacy dispensing platform

Investment/Acquisition Highlights

✓ **Unique value proposition and attractive economics for clients**

- The PharmaTrust MedCentre™ provides a low cost system to enhance efficiencies and profitability of existing pharmacies in addition to providing convenient access to customers 24/7.
- The PharmaTrust MedCentre™ can be placed in any location as a means to attract customers or provide convenience to consumers that results in an additional revenue source for the host.
- The PharmaTrust MedCentre™ infrastructure provides a fully integrated networked pharmacy system allowing high volume call centre type economics to be applied to dispensing. Further, the enterprise system has integration capabilities to both existing pharmacy management systems and patient electronic medical records.



✓ **Regulatory trends support PharmaTrust's business model**

- Remote dispensing of prescriptions is now legal in the Province of Ontario, while British Columbia, Manitoba and Saskatchewan all have approvals pending.
- States of Illinois, Missouri, Wisconsin, North Dakota, Iowa, Montana and Oregon have approved remote dispensing in remote areas or specific venues with seven additional state approvals expected in 2012.

✓ **Significant market potential with global application**

- Market for prescription medicines is forecast to grow globally at a compound annual growth rate of 6.2%.
- While the Company remains focused on core markets in Canada and the US, PharmaTrust has received international inquiries from the UK, Singapore, The Netherlands, Philippines, Saudi Arabia and China, amongst others.
- Global emerging markets offer a significant growth opportunity due to the potential for remote dispensing technology to provide an alternative route to building widespread pharmacy infrastructure.

✓ **Considerable progress to date with large retail US pharmacy and drug store chain**

- Successful product testing over six month period.
- Proof of concept ('POC') trials to commence following completion of security hardening of network and pill-counting functionality.
- Following satisfactory completion of POC, prospect of definitive agreement for scale trial and national roll out.
- Potential national contract with this customer could represent approximately 60% of Company's national US deployments from 2012-15.

✓ **Attractive financial model with strong revenue and deployment visibility**

- Revenue driven by multiple sources including recurring licensing revenue, product sales and upgrades.


ACQUISITION OR INVESTMENT OPPORTUNITY

Revolutionary automated pharmacy dispensing platform

Financial Highlights

- Financial projections for the forecast period 2012 to 2014 represent Management's estimates and judgments about The PharmaTrust MedCentre™ deployments and unit and contract economics.
- While the Company has successfully completed test trials, additional investment will be required to complete the technology and bring The PharmaTrust MedCentre™ to commercialization.
- Based on an updated strategic plan prepared in conjunction with independent technology experts, the Company is projecting revenue growth from \$0.6 million in 2012 to \$247 million in 2014, with positive EBITDA in 2014 of \$50.4 million, based on the existence of a large enterprise client making significant orders in 2013.

Quarterly Forecast Revenue and EBITDA 2012 to 2014



Sales Process

- On May 7, the Ontario Superior Court of Justice appointed PricewaterhouseCoopers Corporate Finance Inc. as the financial advisor to the Monitor to advise and assist the Company with a sales and investor solicitation process.
- The Company is seeking interested parties to invest in or acquire the business or assets of PharmaTrust under a Court approved sales process. The bid deadline is on May 24, 2012.**
- More detailed information will be available to those who execute a Confidentiality Agreement. To obtain a Confidentiality Agreement, or to discuss specific questions regarding this opportunity, please contact the Company or PwCCF.

Contact Information

Kym Anthony
Chairman, PCAS
☎ +1 416-418-8067
✉ kym.anthony@yahoo.com

Eric Castonguay
Managing Director, PwCCF
☎ +1 416 815 5094
✉ eric.castonguay@ca.pwc.com

Rozanne Kibel
Managing Director, PwCCF
☎ +1 416 814 5849
✉ rozanne.kibel@ca.pwc.com

Kaitlin Hogan
Vice President, PwCCF
☎ +1 416 869 2459
✉ kaitlin.e.hogan@ca.pwc.com

The information contained in this document has been taken from the Company's records, information, forecast and predictions. This document has been prepared for general guidance on matters of interest only, and does not constitute professional advice. You should not act upon the information contained in this publication without obtaining specific professional advice. No representation or warranty (express or implied) is given as to the accuracy or completeness of the information contained in this publication, and, to the extent permitted by law, the Company, its Board and Management, PricewaterhouseCoopers Corporate Finance Inc., PricewaterhouseCoopers LLP, its members, employees and agents do not accept or assume any liability, responsibility or duty of care for any consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.